Accurate assessment of the response to NST is of importance, especially in patients with TN and HER2-positive breast cancer, as they have a survival benefit from adjuvant systemic treatment in case of residual invasive disease.10,11 Although surgery may not attribute to local control or survival, it is still essential as diagnostic tool in these patients. Here, ERBB2 is linked to breast cancer.